







home - medicinova, inc.




















































home
company

management team
board of directors
medicinova history
careers

current openings




clinicaldevelopment

development pipeline
core programs

mn-001 (fibrotic diseases)
mn-166 (neurology diseases)
mn-221 (respiratory diseases)


non-core programs

mn-001 (bronchial asthma)
mn-001 (interstitial cystitis)
mn-029 (cancer)
mn-221 (preterm labor)


information request


businessdevelopment

partners & collaborators
information request


investorrelations

press releases
events
media archive
annual reports
sec filings
stock quote – tse
stock quote – nasdaq
historical price lookup
investment calculator
analyst coverage
corporate governance
information request


presentations
contactus
 





japanese site 日本語 




search the site...








 


medicinova is a biopharmaceutical company that is developingnovel therapeutics with a primary focus on neurology, respiratory,and liver diseases with unmet medical needs.








mn-166 for neurology diseases


progressive multiple sclerosis
amyotrophic lateral sclerosis (als)
click here for combat-als webinar
drug dependence


learn more







mn-221 for respiratory diseases


acute exacerbations of asthma
copd exacerbations


learn more







mn-001 for fibrotic diseases


liver fibrosis (nash or others)
pulmonary fibrosis (ipf)


learn more








terms of use
privacy policy
search the site
 


				copyright © 2025 medicinova, inc. all rights reserved.
				designed by keeneyemedia






